Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frank, N. Y.
Right arrow Articles by Frank, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frank, N. Y.
Right arrow Articles by Frank, M. H.
[Cancer Research 65, 4320-4333, May 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma

Natasha Y. Frank1, Armen Margaryan2, Ying Huang3, Tobias Schatton2, Ana Maria Waaga-Gasser4, Martin Gasser4, Mohamed H. Sayegh2, Wolfgang Sadee3 and Markus H. Frank2

1 Department of Genetics, Children's Hospital Boston and 2 Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts; 3 Program in Pharmacogenomics, Department of Pharmacology, The Ohio State University, Columbus, Ohio; and 4 Department of Surgery, University of Würzburg Medical School, Würzburg, Germany

Requests for reprints: Markus H. Frank, Transplantation Research Center, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, 75 Francis Street, Boston, MA 02115. Phone: 617-919-2993; Fax: 617-730-0129; E-mail: mfrank{at}rics.bwh.harvard.edu.

Enhanced drug efflux mediated by ABCB1 P-glycoprotein and related ATP-binding cassette transporters is one of several mechanisms of multidrug resistance thought to impair chemotherapeutic success in human cancers. In malignant melanoma, its potential contribution to chemoresistance is uncertain. Here, we show that ABCB5, which functions as a determinant of membrane potential and regulator of cell fusion in physiologic skin progenitor cells, is expressed in clinical malignant melanoma tumors and preferentially marks a subset of hyperpolarized, CD133+ stem cell phenotype-expressing tumor cells in malignant melanoma cultures and clinical melanomas. We found that ABCB5 blockade significantly reversed resistance of G3361 melanoma cells to doxorubicin, an agent to which clinical melanomas have been found refractory, resulting in a 43% reduction in the LD50 from 4 to 2.3 µmol/L doxorubicin (P < 0.05). Our results identified ABCB5-mediated doxorubicin efflux transport as the underlying mechanism of resistance, because ABCB5 blockade significantly enhanced intracellular drug accumulation. Consistent with this novel ABCB5 function and mechanism in doxorubicin resistance, gene expression levels of the transporter across a panel of human cancer cell lines used by the National Cancer Institute for drug screening correlated significantly with tumor resistance to doxorubicin (r = 0.44; P = 0.016). Our results identify ABCB5 as a novel drug transporter and chemoresistance mediator in human malignant melanoma. Moreover, our findings show that ABCB5 is a novel molecular marker for a distinct subset of chemoresistant, stem cell phenotype-expressing tumor cells among melanoma bulk populations and indicate that these chemoresistant cells can be specifically targeted via ABCB5 to enhance cytotoxic efficacy.




This article has been cited by other articles:


Home page
JCOHome page
S. E. Zabierowski and M. Herlyn
Melanoma Stem Cells: The Dark Seed of Melanoma
J. Clin. Oncol., June 10, 2008; 26(17): 2890 - 2894.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. P. Hill and R. Perris
"Destemming" Cancer Stem Cells
J Natl Cancer Inst, October 3, 2007; 99(19): 1435 - 1440.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Y. Suryo Rahmanto, L.L. Dunn, and D.R. Richardson
Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo
Carcinogenesis, October 1, 2007; 28(10): 2172 - 2183.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
V. Sharma, C. Joseph, S. Ghosh, A. Agarwal, M. K. Mishra, and E. Sen
Kaempferol induces apoptosis in glioblastoma cells through oxidative stress
Mol. Cancer Ther., September 1, 2007; 6(9): 2544 - 2553.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.